Trial Profile
Antihypertensive Effect of Different Doses of ROSTAFUROXIN in Comparison With Losartan, Assessed by Office and Ambulatory Blood Pressure Monitoring in a Hypertensive Population Selected According to a Specific Genetic Profile.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Apr 2019
Price :
$35
*
At a glance
- Drugs Rostafuroxin (Primary) ; Losartan
- Indications Hypertension
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors CVie Therapeutics; Windtree Therapeutics
- 22 Dec 2015 According to a Lee's Pharmaceutical Holdings media release, enrollment has been completed in Italy in November 2015 and the first patient from Taiwan has been enrolled on 18 December 2015. The company expects to complete enrollment in Taiwan in June 2016.
- 12 Jun 2013 Status changed from planning to recruiting, according to a Lee's Pharmaceutical Holdings media release. The first patient has been enrolled.
- 13 Aug 2012 New trial record